American Food and Medication Quality Supervision (FDA) approved Adukanumab preparation to combat Alzheimer’s disease. This happened for the first time in 20 years.
Russian BBC service writes that the drug developed by Biogen will go on sale under the commercial name Aduhelm. The drug acts on deep reasons, and not on the symptoms of Alzheimer’s disease, the most common type of senile dementia.
Adukanumab destroys the amyloid – protein that shapes a bunch of bunches in the brain, damaging cells and raising problems with memory, thinking and communication. The drug is suitable for patients under 80 years old and with the initial stage of the disease.
In the past 10 years, over a hundred treatments of Alzheimer’s disease were considered, but none of themselves justified. Adukanumab is not a panacea, notes BBC, many doctors express doubts about his merits. But his registration in the United States will give a strong impetus to research in the field of dealing with dementia, traditionally underfunded in comparison with oncology or cardiology.
In March 2019, the international tests of Adumanukaba with the participation of three thousand people were interrupted at the final stage, when it turned out that the drug obtained in the form of a monthly injection does not give a positive result compared to placebo. However, at the end of the same year, the American manufacturer Biogen analyzed a larger amount of data and found that Adukanumab significantly slows down the weakening of cognitive abilities, if applied at higher doses.